Stock RCE RECCE PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.66 AUD +3.94% Intraday chart for Recce Pharmaceuticals Ltd +15.79% +23.36%
Apr. 17 Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice CI
Apr. 16 Recce Pharmaceuticals Advances Production of Anti-Infective Medication MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
AQ
Recce Pharmaceuticals Provides Business Update
AQ
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
AQ
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
AQ
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
AQ
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
AQ
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
AQ
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
AQ
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
AQ
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
AQ
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
AQ
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
AQ
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
AQ
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
AQ
Antimicrobial resistance with Recce Pharmaceuticals
AQ
Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharma welcomes approval for faster RECCE327 infusion rate
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCE Stock
  4. News Recce Pharmaceuticals Ltd
  5. Press Releases